Skip to main content Skip to main content
VitalDecades logo VitalDecades

Biomarker library / Lipids

Apolipoprotein B (ApoB)

Also called apo B, apoB-100

Each atherogenic lipoprotein particle (LDL, VLDL, IDL, lipoprotein(a)) carries exactly one apolipoprotein B molecule, so ApoB is a count of those particles rather than the cholesterol they carry. Two people can have the same LDL-C and different particle counts.

By , Longevity & Research Sources checked Corrected How pages are checked

01  /  Guideline numbers

What the guidelines say about this number

Save this result

Stored on your account and never shared. We are not sending email yet, so band-change alerts will not arrive until we turn sending on. Export or delete it any time from My numbers.

Population Adults without ASCVD, primary prevention (2026 ACC/AHA risk enhancer)
Category Risk-enhancing factor
Range 120 or higher mg/dL Listed in one row with LDL-C persistently 160 to 189 mg/dL or non-HDL-C 190 to 219 mg/dL. Read from ACC's reproduction of the guideline's Table 13.
Population PREVENT-ASCVD under 10% with triglycerides 150 to 499, or diabetes without risk factors (2026 ACC/AHA)
Category Optional apoB goal
Range under 90 mg/dL The guideline's diabetes and hypertriglyceridemia algorithms label this apoB goal optional. Read from ACC's reproduction of the guideline's Figure 1 and those algorithms.
Population PREVENT-ASCVD 10% or higher with triglycerides 150 to 499, or diabetes with risk factors (2026 ACC/AHA)
Category Optional apoB goal
Range under 70 mg/dL Figure 1 also sets it for hypertriglyceridemia with clinical ASCVD not at very high risk. The guideline's algorithms for diabetes, high triglycerides and clinical ASCVD label this apoB goal optional. Read from ACC's reproduction of the guideline's figures.
Population Clinical ASCVD at very high risk (2026 ACC/AHA, optional goal)
Category Optional apoB goal
Range under 55 mg/dL Read from ACC's reproduction of the guideline's Figures 1 and 11.
Population Untreated US adults, NHANES 2005 to 2016 (NLA 2024)
Category Population median (50th percentile)
Range 90 mg/dL 90th percentile 125 mg/dL; 95th percentile 137 mg/dL.

Normal vs optimal

Lab reference intervals for ApoB vary and are typically population-based, not outcome-based. The numbers above are a risk enhancer and optional goals from the 2026 guideline plus a US population median, and the goals differ by risk category. If your report prints a single "normal" cutoff, ask which body it comes from.

02  /  Why it matters

What the number tells you

In 2024 the National Lipid Association wrote that "Specific apoB thresholds have not been suggested in U.S. guidelines and recommendations". That changed with the 2026 ACC/AHA dyslipidemia guideline, published online March 13, 2026, which the NLA co-authored and endorsed. Its table of risk enhancers lists apoB of 120 mg/dL or higher in one row with an LDL-C persistently 160 to 189 mg/dL or a non-HDL-C of 190 to 219. Its goal figure sets apoB goals of under 90, under 70 and under 55 mg/dL, tied to triglycerides of 150 to 499, diabetes, or clinical atherosclerotic cardiovascular disease (ASCVD), and its treatment algorithms for diabetes, high triglycerides and clinical ASCVD label the apoB goals optional. ACC's September 2026 feature on the guideline describes "an optional Apo-B goal in conditions associated with increased remnant lipoproteins". Two one-page corrections to the guideline were published on June 22 and September 8, 2026, and we could not read them, so the numbers here are as printed in ACC's reproduction of the guideline's tables and figures, read October 19, 2026.

  • Population context (NLA 2024, NHANES 2005 to 2016, untreated US adults): the median ApoB is 90 mg/dL, the 90th percentile 125, the 95th percentile 137.

03  /  In practice

Testing and what moves it

When it is tested

  • Not part of a standard lipid panel; ordered separately or as part of an advanced lipid test.
  • The AHA's release on the 2026 guideline says apoB may be used to assess residual risk and guide treatment in people with cardiovascular-kidney-metabolic syndrome, type 2 diabetes, high triglycerides or known cardiovascular disease who have reached their LDL-C and non-HDL-C goals.

What raises it

  • The same drivers as LDL-C plus insulin resistance and high triglycerides, which raise the number of small dense particles without a matching rise in LDL-C.

What lowers it

  • Statins, ezetimibe and PCSK9 inhibitors lower ApoB alongside LDL-C; weight loss and better glycemic control lower the triglyceride-rich fraction.

04  /  Related

Frequently asked questions

Is ApoB better than LDL cholesterol?

ApoB counts atherogenic particles; LDL-C measures the cholesterol they carry. The NLA 2024 consensus supports using ApoB to refine risk and guide intensity, especially when triglycerides are high or LDL-C looks discordant with overall risk. US guidelines have not replaced LDL-C with ApoB: ACC's July 2026 article on the 2026 guideline says "LDL-C remains the mainstay of cholesterol screening and target".

What ApoB should I aim for?

It depends on your group. The 2026 ACC/AHA guideline sets apoB goals of under 90 mg/dL at a 10-year PREVENT-ASCVD risk under 10% with triglycerides of 150 to 499, or with diabetes without risk factors; under 70 at a risk of 10% or more with those triglycerides, or with diabetes and risk factors; and under 55 for clinical ASCVD at very high risk. Its treatment algorithms for diabetes, high triglycerides and clinical ASCVD label these apoB goals optional. The US median of 90 mg/dL in untreated adults is a population statistic, not a goal.

2 documents set the numbers on this page. The oldest was published in 2024, the newest in 2026.

We last re-read these sources on . How we verify.

Edited by (Longevity & Research). How pages are checked